Document Detail

Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa.
MedLine Citation:
PMID:  8774986     Owner:  NLM     Status:  MEDLINE    
The purpose of this study was to clarify the effect of lansoprazole on basic fibroblast growth factor (bFGF) during the healing of gastric ulcers in comparison with famotidine and rebamipide. Alteration of the localization and concentration of bFGF was examined in gastric mucosa obtained endoscopically from ulcer patients. The bFGF content was estimated by enzyme-linked immunosorbent assay and the localization of bFGF immunoreactivity was determined by indirect immunohistochemical study using monoclonal antibodies. In the lansoprazole-treated cases, the content and the histochemical immunoreactive area of bFGF significantly increased 4 weeks after the treatment, compared with the group treated with rebamipide and the control group. In the famotidine-treated group, the concentration of bFGF significantly increased, compared with the rebamipide-treated group, and not with control. The number of binding sites for [125I]bFGF, as determined by in vitro autoradiography, also significantly increased in the lansoprazole-treated group. Therefore, an increase in bFGF concentration and receptor distribution was shown to be brought about by treatment with lansoprazole.
M Nakamura; M Oda; Y Akiba; J Inoue; T Ito; M Tsuchiya; H Ishii
Related Documents :
25043716 - Nitric oxide and reactive species are modulated in the polyphenol-induced ductus arteri...
18058356 - Orthoptists' management of amblyopia - a case-based survey.
1031536 - A case of simultaneous interstitial bilateral pregnancy.
9009686 - Ovarian pregnancies treated with methotrexate.
10828176 - The role of iodine in brain development.
12206926 - Endometrial vascularity and ongoing pregnancy after ivf.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of clinical gastroenterology     Volume:  21 Suppl 1     ISSN:  0192-0790     ISO Abbreviation:  J. Clin. Gastroenterol.     Publication Date:  1995  
Date Detail:
Created Date:  1996-12-04     Completed Date:  1996-12-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7910017     Medline TA:  J Clin Gastroenterol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S24-9     Citation Subset:  IM    
Department of Internal Medicine, Tokyo Denryoku Hospital, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Ulcer Agents / therapeutic use*
Binding Sites
Enzyme-Linked Immunosorbent Assay
Fibroblast Growth Factor 2 / drug effects,  metabolism*
Omeprazole / analogs & derivatives*,  therapeutic use
Stomach Ulcer / drug therapy*,  metabolism,  pathology
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 103107-01-3/Fibroblast Growth Factor 2; 103577-45-3/lansoprazole; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of extracellular matrix in injury to gastric mucosa by indomethacin.
Next Document:  Gastric mucosal cell proliferation and TGF alpha in the healing of peptic ulcers in human subjects.